(NASDAQ: XNCR) Xencor's forecast annual revenue growth rate of -3.95% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Xencor's revenue in 2025 is $150,132,000.On average, 16 Wall Street analysts forecast XNCR's revenue for 2025 to be $9,374,766,370, with the lowest XNCR revenue forecast at $7,418,119,520, and the highest XNCR revenue forecast at $15,101,171,879. On average, 16 Wall Street analysts forecast XNCR's revenue for 2026 to be $8,982,008,791, with the lowest XNCR revenue forecast at $4,839,059,021, and the highest XNCR revenue forecast at $19,430,788,615.
In 2027, XNCR is forecast to generate $9,724,677,668 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $21,564,533,429.